(Q40122469)

17 September 2017

title

Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine (English)

1 reference

17 September 2017

0 references

Annelies Wilder-Smith

series ordinal

1

object named as

Annelies Wilder-Smith

1 reference

17 September 2017

2

Eduardo Massad

1 reference

17 September 2017

publication date

17 January 2016

1 reference

Expert Review of Vaccines

17 September 2017

published in

1 reference

17 September 2017

volume

15

1 reference

17 September 2017

issue

4

1 reference

17 September 2017

page(s)

437-441

1 reference

Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment

17 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1143366

Identifying protective dengue vaccines: guide to mastering an empirical process

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1143366

Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1143366

Efficacy of a tetravalent dengue vaccine in children in Latin America.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1143366

Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1143366

Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1143366

From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1143366

Dengue vaccines: dawning at last?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1143366

Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1143366

Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1143366

A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1143366

Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1143366

Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1143366

Epidemiological trends of dengue disease in Thailand (2000-2011): a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1143366

Epidemiological trends of dengue disease in Brazil (2000-2010): a systematic literature search and analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1143366

Vaccine preventable disease incidence as a complement to vaccine efficacy for setting vaccine policy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1143366

The number needed to vaccinate (NNV) and population extensions of the NNV: comparison of influenza and pneumococcal vaccine programmes for people aged 65 years and over

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1143366

PUBLIC HEALTH. Dengue vaccines at a crossroad

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1143366

10.1586/14760584.2016.1143366

21 January 2018

Identifiers

DOI

1 reference

17 September 2017

1 reference